Pharmaceuticals company Kwality Pharmaceuticals announced Q1FY27 results Consolidated Financial Highlights: Total Revenue: For Q1FY27, the consolidated total revenue stood at Rs 16,297.49 lakh, representing an increase of 45.70% compared to Rs 11,185.47 lakh in Q1FY26 (YoY) and a growth of 3.04% from Rs 15,817.17 lakh in Q4FY26 (QoQ). Revenue from Operations: Net revenue from operations in Q1FY27 was Rs 16,235.22 lakh, up by 45.63% from Rs 11,147.90 lakh in Q1FY26 (YoY) and up by 3.33% from Rs 15,711.36 lakh in Q4FY26 (QoQ). Net Profit: The company reported a consolidated net profit for the period of Rs 2,562.23 lakh in Q1FY27, marking a significant growth of 114.96% compared to Rs 1,191.97 lakh in Q1FY26 (YoY) and an increase of 1.23% from Rs 2,531.05 lakh in Q4FY26 (QoQ). Earnings Per Share (EPS): Basic and diluted EPS for Q1FY27 stood at Rs 24.69, compared to Rs 11.49 in Q1FY26 and Rs 24.39 in Q4FY26. Total Comprehensive Income: The total comprehensive income for the period was Rs 2,571.23 lakh in Q1FY27, reflecting robust growth compared to Rs 1,207.08 lakh in Q1FY26. Standalone Financial Highlights: Total Revenue: Standalone total revenue for Q1FY27 was Rs 16,297.49 lakh, showing an increase of 45.70% from Rs 11,185.47 lakh in Q1FY26 (YoY) and a rise of 3.23% from Rs 15,788.04 lakh in Q4FY26 (QoQ). Revenue from Operations: Standalone net revenue from operations stood at Rs 16,235.22 lakh in Q1FY27, compared to Rs 11,147.90 lakh in Q1FY26 and Rs 15,682.24 lakh in Q4FY26. Net Profit: The standalone net profit reached Rs 2,562.68 lakh in Q1FY27, a growth of 114.77% against Rs 1,193.22 lakh in Q1FY26 (YoY) and a growth of 1.33% from Rs 2,529.11 lakh in Q4FY26 (QoQ). Earnings Per Share (EPS): Standalone basic and diluted EPS was Rs 24.70 for Q1FY27, compared to Rs 11.50 in Q1FY26 and Rs 24.37 in Q4FY26. Business Highlights: Guidance Update: Building on the momentum of a strong FY26, the management has raised FY27 guidance across key metrics: Revenue: Rs 700+ crore (+39%+ YoY). EBITDA: Rs 189-196+ crore (27-28%+ margin). PAT: Rs 109+ crore (~15.5%+ margin). R&D; and Clinical Programme: During the quarter, the company completed 13 Bioequivalence (BE) studies (7 from the General unit, 2 from Beta Lactam, and 4 from Oncology) as part of its 40-molecule BE programme. Filings have been made in 15+ countries. Product Registrations: The company secured 15+ new key product registrations across Malaysia, Algeria, Peru, and Mexico during the quarter. Biologics Front: Received approval to initiate pre-clinical batches for Pembrolizumab, adding a second biologics candidate. Erythropoietin has progressed to the clinical trial stage. Facility Update: Construction of the Hormone manufacturing facility is on schedule, with completion anticipated by November 2026. Global Presence: The company operates five manufacturing facilities and has a presence in over 70+ countries. Result PDF